PURPOSE: Given that the clinical course of @entity901 -induced @entity16 is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. METHODS: @entity697 was evaluated in @entity1 receiving adjuvant FOLFOX ( @entity1487 , @entity4181 , and @entity901 ) on study N08CB (North Central @entity5 Treatment Group, Alliance). Acute @entity16 was assessed by having @entity1 complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic @entity2359 was assessed with use of the 20-item, European Organisation for Research and Treatment of @entity5 quality-of-life questionnaire for @entity1 with chemotherapy-induced @entity1897 . RESULTS: Three hundred eight (89%) of the 346 @entity1 had at least one symptom of acute @entity16 with the first cycle of FOLFOX; these symptoms included sensitivity to touching cold items (71%), sensitivity to swallowing cold items (71%), throat discomfort (63%), or muscle cramps (42%). Acute symptoms peaked at day 3 and improved, although they did not always resolve completely between treatments. These symptoms were about twice as severe in cycles 2 through 12 as they were in cycle 1. For chronic @entity2359 , tingling was the most severe symptom, followed by @entity1183 and then @entity158 . During chemotherapy, symptoms in the hands were more prominent than they were in the feet; by 18 months, symptoms were more severe in the feet than they were in the hands. @entity1 with more severe acute @entity16 during the first cycle of therapy experienced more chronic sensory @entity2359 (P < .0001). CONCLUSION: Acute @entity901 -induced @entity16 symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of @entity697 .

Clinical Course of @entity901 -Induced XXXX : Results From the Randomized Phase III Trial N08CB (Alliance).

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity697 :: ('MESH:D000208', 'Disease') :: ['Acute and chronic neuropathy', 'acute and chronic neuropathies'] @entity1183 :: ('MESH:D006987', 'Disease') :: ['numbness'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']
@entity16 :: (MESH:D009422,Disease) :: ['Neuropathy']
